Sall4 in “Stemness”-Driven Hepatocarcinogenesis
Menée sur deux cohortes de patients atteints d'un carcinome hépatocellulare à Singapour et Hong Kong, cette étude met en évidence l'association entre une surexpression de la protéine oncofœtale SALL4 et un pronostic défavorable
Hepatocellular carcinoma is the most common and deadly cause of primary liver cancer. Although the incidence of hepatocellular carcinoma is highest in Asia and sub-Saharan Africa, the steadily increasing incidence in traditionally low-incidence regions such as northern Europe and the United States is a considerable public health problem. Despite implementation of surveillance programs, the majority of patients still present with advanced stages of the disease, for which curative options are limited.
Currently, the standard-of-care treatment for advanced liver cancer is limited to the multiple receptor tyrosine kinase inhibitor sorafenib.2 Furthermore, development of new therapies is often hampered by the molecular . .
New England Journal of Medicine , éditorial, 2012